The FDA has reopened a docket to continue to receive public comments regarding LASIK. Information and comments submitted to the docket will assist the FDA in identifying ways in which the agency can improve its public outreach efforts regarding the risks and long-term consequences of LASIK.
Read more...November 2009 Archives
"The FDA's mission is to serve and protect the public, not to serve industry," says a 126-signatory letter to CDRH acting director Jeffrey M. Shuren, seeking a public health advisory on "the high incidence of adverse events and long-term consequences associated with LASIK surgery."
Read more...
